Investigation Report on China’s Repaglinide Market, 2018-2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Investigation
Report on China’s Repaglinide Market, 2018-2022”
report has
been added to ResearchAndMarkets.com’s offering.

Since the 1980s, China’s economic development has improved living
standards and urbanization level, which significantly increases the
incidence of obesity, diabetes and other non-communicable diseases in
China. And population aging and other factors sharply raise the
incidence of type 2 diabetes. The number of type 2 diabetic patients in
China surpassed 110 million at the end of 2017, and is growing by 1.5
million to 2 million every year.

Insulin secretagogues are mainly used to treat type 2 diabetes. Compared
with sulfonylureas, insulin secretagogues have short-lasting effects and
cause few hypoglycemia reactions.

Developed by Danish company Novo Nordisk and German company Boehringer
Ingelheim, Repaglinide is a non-sulfonylurea-based insulin secretagogue
used to control postprandial hyperglycemia. The drug was launched in the
U.S. in Apr.1998. Entering China in 2000, Novo Nordisk’s NovoNorm has
few competitors.

According to market research, by sales value, the market share of Novo
Nordisk was about 80% in 2017, while the market share of Jiangsu Hansoh
Pharmaceutical Co., Ltd., its major competitor, was less than 20%. But
Novo Nordisk’s market share is sliding because NovoNorm is more
expensive than China-made generic drugs. In 2017, the sales value of
Repaglinide was about CNY 272 million in China, representing a slow
decline from 2013 to 2017. Considering good efficacy, reasonable prices,
and the increasing number of type 2 diabetic patients, Repaglinide will
still have certain growth potential in China in the next few years.

Topics Covered:

  • Situation of type 2 diabetes in China
  • Size of China’s Repaglinide market
  • Major Repaglinide manufacturers in China
  • Competition on China’s Repaglinide market
  • Retail prices of Repaglinide in China
  • Prospect of China’s Repaglinide market from 2018 to 2022

Key Topics Covered:

1 Relevant Concepts of Repaglinide

2 Sales of Repaglinide in China, 2013-2017

3 Major Repaglinide Manufacturers in China, 2013-2017

4 Prices of Repaglinide in China, 2017-2018

5 Prospect of China’s Repaglinide Market, 2018-2022

Companies Mentioned

  • Beijing Beilu Pharmaceutical Co. Ltd.
  • Beijing Winsunny Pharmaceutical Co. Ltd.
  • Boehringer Ingelheim
  • Jiangsu Hansoh Pharmaceutical Co. Ltd.
  • Novo Nordisk
  • Tianjin Kangrui Pharmaceutical Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/36qp3b/investigation?w=4


Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Endocrine
and Metabolic Disorders Drugs


I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.com for scheduling information.